29th Nov 2017 12:20
29 November 2017
Diurnal Group plc
("Diurnal" or the "Company")
Directors' Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, received notification of the following Directors' share purchases on 27 November 2017:
Martin Whitaker, Chief Executive Officer, purchased 3,703 Ordinary Shares at a price of 135 pence per Ordinary Share. Following the transaction Martin Whitaker has a total interest of 50,729 Ordinary Shares, representing 0.10% of the total voting rights.
Richard Bungay, Chief Financial Officer, purchased 2,222 Ordinary Shares at a price of 135 pence per Ordinary Share. Following the transaction Richard Bungay has a total interest of 2,222 Ordinary Shares, representing 0.004% of the total voting rights.
Richard Ross, Chief Scientific Officer, purchased 1,481 ordinary shares in the Company ("Ordinary Shares") at a price of 135 pence per Ordinary Share. Following the transaction Richard Ross has a total interest of 1,555,425 Ordinary Shares, representing 2.96% of the total voting rights.
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, CEO | |
Richard Bungay, CFO | |
Numis Securities Ltd (Nominated Adviser) | +44 (0)20 7260 1000 |
Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield | |
Corporate Broking: James Black | |
Panmure Gordon (UK) Limited (Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley / Duncan Monteith | |
Corporate Broking: Tom Salvesen | |
FTI Consulting | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
DEALING NOTIFICATION FORMFOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Martin Whitaker | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Chief Executive Officer | ||||
b) | Initial notification/Amendment: | Initial | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | 213800I2HNUNZN1LDH29 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 5 pence each in Diurnal Group plc GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s):
|
| ||||
d) | Aggregated information:
| Aggregated volume: 3,703 Price: £4999.05 | ||||
e) | Date of the transaction: | 27 November 2017 | ||||
f) | Place of the transaction: | XLON | ||||
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Richard Bungay | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Chief Financial Officer | ||||
b) | Initial notification/Amendment: | Initial | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | 213800I2HNUNZN1LDH29 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 5 pence each in Diurnal Group plc GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s):
|
| ||||
d) | Aggregated information:
| Aggregated volume: 2,222 Price: £2,999.70 | ||||
e) | Date of the transaction: | 27 November 2017 | ||||
f) | Place of the transaction: | XLON | ||||
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Richard Ross | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Chief Scientific Officer | ||||
b) | Initial notification/Amendment: | Initial | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | 213800I2HNUNZN1LDH29 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 5 pence each in Diurnal Group plc GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s):
|
| ||||
d) | Aggregated information:
| Aggregated volume: 1,481 Price: £1,999.35 | ||||
e) | Date of the transaction: | 27 November 2017 | ||||
f) | Place of the transaction: | XLON | ||||
Related Shares:
DNL.L